" class="no-js "lang="en-US"> Paul Wotton - Medtech Alert
Saturday, September 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Paul Wotton

Paul Wotton

About Paul Wotton

Experienced Board Member, Inventor and Serial Entrepreneur with a demonstrated history of success in the biotechnology industry. Skilled in Biotechnology, Product Development, Life Sciences and Transactions. Strong business development professional with a Ph.D. focused in Pharmaceutical Sciences from the University of Nottingham. Winner EY Entrepreneur of the Year 2014, NJ Region.

Related Story

Diseases

 MD Anderson and Obsidian Therapeutics Announce FDA Clearance of IND Application for Novel TIL Therapy Obx-115 | Pharmtech Focus

MD Anderson and Obsidian Therapeutics Announce FDA Clearance of IND Application for Novel TIL Therapy Obx-115

July 25 2022

The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug Administration (FDA) clearance […]

Appointments

 Obsidian Therapeutics Appoints Lee Giguere

Obsidian Therapeutics Appoints Lee Giguere, J.D., as Chief Legal Officer and Corporate Secretary

December 8 2021

Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced the […]

Appointments

 Obsidian Therapeutics Appoints Maria Fardis

Obsidian Therapeutics Appoints Maria Fardis, Ph.D., to Board of Directors

October 22 2021

Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced the […]